Development of a clinical microscale dosimetry framework for radiopharmaceutical therapy

EFOMP Working Group; Belgique; Remote; USD 25,000 - 35,000; Full time

Benefits offered by this job

4-year scholarship

Job summary

A leading research initiative in medical physics is seeking a PhD candidate to develop a clinical microscale dosimetry framework for PSMA-targeted radiopharmaceutical therapy. The project will focus on improving precision medicine in prostate cancer by enhancing dose–response assessments and individualized treatment planning through innovative computational modeling and imaging techniques. Candidates with backgrounds in medical physics or biomedical/nuclear sciences are encouraged to apply. This four-year scholarship position offers an opportunity to work at the intersection of physics and clinical practices.

Qualifications

• Background in medical physics is required.
• Experience in biomedical or nuclear sciences is necessary.

Responsibilities

• Develop a clinical microscale dosimetry framework.
• Combine PBPK modeling with anatomical representations and imaging data.

Skills

Medical physics

Biomedical or nuclear sciences

Job description

Development of a clinical microscale dosimetry framework for radiopharmaceutical therapy

Position: PhD candidate

Application closes at: Mar 31st, 2026 23:00

Radiopharmaceutical therapy (RPT) delivers radiation directly to tumor cells, but current clinical practice still relies on fixed administered activities and whole-organ dosimetry. This overlooks heterogeneous radiopharmaceutical distribution within organs, which is particularly critical for dose‑limiting tissues such as the kidneys, where localized high absorbed doses may cause toxicity even when average organ doses appear safe.

This PhD project advances precision medicine in prostate cancer by developing a clinical microscale dosimetry framework for PSMA‑targeted RPT.

By combining mechanistic physiologically based pharmacokinetic (PBPK) modeling with high‑resolution anatomical representations, preclinical biodistribution data, clinical PET/SPECT imaging, and Monte Carlo‑based dose calculations, the project aims to enable more accurate dose–response assessment and individualized treatment planning.

Embedded in a broader research initiative, this PhD offers the opportunity to work at the interface of physics, computational modeling, and clinical translation.

University promoter: Michel Koole (KU Leuven)

Scholarship available (4 years): yes

Candidate required background:

• Medical physics
• Biomedical or nuclear sciences